Understanding the mechanisms of the anabolic action of PTH on bone is important both because PTH represents the first anabolic agent useful to treat osteoporosis and because a molecular understanding of PTH's anabolic action will allow the development of even more effective anabolic agents. Our goal here is to use in vivo models to establish the roles of specific """"""""second messenger"""""""" pathways responsible for the various actions of PTH that, in sum, result in an increase in bone mass. Understanding of the multiple, specific pathways leading in varying ways to increased bone will make possible the next rational generation of anabolic agents. We also want to understand these mechanisms to understand better the roles of PTH and PTHrP in normal physiology and disease. PTH and PTHrP stimulate both bone formation and bone resorption through activation of the PTH/PTHrP receptor (PTHR1) in cells of the osteoblast lineage. The PTHR1 activates several heterotrimeric G proteins, with Gs and Gq/11 being the best characterized. We will use two genetic models that allow the separation of the actions of these downstream mediators in vivo. One model uses a """"""""knock-in"""""""" mouse in which the normal PTHR1 gene has been mutated to selectively disrupt the activation of phospholipase C by the Gq/11 pathway without affecting activation of Gs. The other model is a conditional knockout in which the osterix promoter, active in early osteoblasts, drives the expression of ere recombinase in a way that can be suppressed by tetracycline derivatives (""""""""tet-off""""""""). This ere is used to ablate expression of Gsa postnatally in early cells of the osteoblast lineage through mating with a Gsa floxed mouse and administration of doxycycline for various times. Three models of receptor activation (continuous elevation of PTH through minipump infusion or low calcium diet, and once daily injection of PTH) will be used to determine the roles of distinct pathways in the variety of actions of the PTHR1 on cells of the osteoblast lineage.
Aim 1. Role of PLC signaling in actions of the PTHR1 in bone. Models of intermittent and continuous PTH administration will be used to determine the role of PTHR1 activation of PLC in bone.
Aim 2. Role of Gs signaling in cells of the osteoblast lineage. Comparison of mice missing Gsa in osteoblastic cells with the same mice exposed to continuous or intermittent elevation of PTH levels should allow identification of the responses to activation of the PTHR1 that require Gsalpha

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Program Projects (P01)
Project #
5P01DK011794-44
Application #
8374992
Study Section
Special Emphasis Panel (ZDK1-GRB-9)
Project Start
1997-08-01
Project End
2013-11-30
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
44
Fiscal Year
2012
Total Cost
$377,509
Indirect Cost
$166,619
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Christov, Marta; Clark, Abbe R; Corbin, Braden et al. (2018) Inducible podocyte-specific deletion of CTCF drives progressive kidney disease and bone abnormalities. JCI Insight 3:
Dedic, Christopher; Hung, Tin Shing; Shipley, Alan M et al. (2018) Calcium fluxes at the bone/plasma interface: Acute effects of parathyroid hormone (PTH) and targeted deletion of PTH/PTH-related peptide (PTHrP) receptor in the osteocytes. Bone 116:135-143
Mizuhashi, Koji; Ono, Wanida; Matsushita, Yuki et al. (2018) Resting zone of the growth plate houses a unique class of skeletal stem cells. Nature 563:254-258
Hanna, Patrick; Grybek, Virginie; Perez de Nanclares, Guiomar et al. (2018) Genetic and Epigenetic Defects at the GNAS Locus Lead to Distinct Patterns of Skeletal Growth but Similar Early-Onset Obesity. J Bone Miner Res 33:1480-1488
Wein, Marc N; Foretz, Marc; Fisher, David E et al. (2018) Salt-Inducible Kinases: Physiology, Regulation by cAMP, and Therapeutic Potential. Trends Endocrinol Metab 29:723-735
Bastepe, Murat (2018) GNAS mutations and heterotopic ossification. Bone 109:80-85
Kim, Sang Wan; Lu, Yanhui; Williams, Elizabeth A et al. (2017) Sclerostin Antibody Administration Converts Bone Lining Cells Into Active Osteoblasts. J Bone Miner Res 32:892-901
Roszko, Kelly L; Bi, Ruiye; Gorvin, Caroline M et al. (2017) Knockin mouse with mutant G?11 mimics human inherited hypocalcemia and is rescued by pharmacologic inhibitors. JCI Insight 2:e91079
Grigelioniene, Giedre; Nevalainen, Pasi I; Reyes, Monica et al. (2017) A Large Inversion Involving GNAS Exon A/B and All Exons Encoding Gs? Is Associated With Autosomal Dominant Pseudohypoparathyroidism Type Ib (PHP1B). J Bone Miner Res 32:776-783
Balani, Deepak H; Ono, Noriaki; Kronenberg, Henry M (2017) Parathyroid hormone regulates fates of murine osteoblast precursors in vivo. J Clin Invest 127:3327-3338

Showing the most recent 10 out of 215 publications